Summary
Researchers at the Paul Scherrer Institute have developed and analyzed an innovative light-switchable active pharmaceutical ingredient for high blood pressure. The molecule can be switched between two forms using light, which directly influences its therapeutic efficacy in the body. This discovery opens new possibilities for more precise medications with targeted light control and has been published in the renowned scientific journal Angewandte Chemie.
People
- Research team of the Paul Scherrer Institute (PSI)
Topics
- Photoswitchable active ingredients
- Hypertension therapy
- Precision medicine
- Molecular pharmacokinetics
Clarus Lead
Swiss researchers have achieved a breakthrough in the development of light-controlled medications. The PSI team investigated how a blood pressure-reducing molecule transforms from one form to another in fractions of a second – triggered by light. These findings enable the development of pharmaceuticals whose effects can be precisely and non-invasively controlled within the organism, offering significant advantages for patient safety and therapeutic success.
Detailed Summary
The Paul Scherrer Institute has examined a photoswitchable active ingredient for hypertension that changes its molecular structure when exposed to light. The researchers documented in real time how the molecule oscillates between two stable states and how these structural changes influence biological activity in the human body. These findings form the scientific foundation for a new class of medications with optical control.
The application of light-controlled active ingredients could enable patients to activate or deactivate their blood pressure medication through external light stimulation – without side effects from systemic exposure. This reduces potential adverse effects and significantly increases therapeutic precision.
Key Findings
- Light-switchable molecules can change their structure and efficacy within fractions of a second
- The PSI has documented the molecular dynamics of this transformation for the first time
- Optically controlled medications could make hypertension therapies more precise and safer
- This technology opens up perspectives for applications in other therapeutic areas
Critical Questions
Data Quality: What experimental methods were used to observe the molecular transformation, and how reliable are these under physiological conditions?
Translation Risk: How is it ensured that the light-switchability observed in the laboratory also functions with sufficient efficiency in living organisms?
Safety Validation: What adverse side effects could result from the light exposure itself or from intermediate products of the molecular transformation?
Regulatory Hurdles: What additional approval requirements are to be expected, given that this is a novel mode of action?
Practical Applicability: How deeply must light penetrate into tissue, and is non-invasive application realistic?
Comparability: How does optical control perform compared to conventional dosing strategies (e.g., sustained-release formulations)?
Source List
Primary Source: Blood pressure reducer with light switch – Paul Scherrer Institute (PSI) Press Release from March 19, 2026 https://www.news.admin.ch/de/newnsb/2KSlb9dY1bQ2GNC2FpszG
Verification Status: ✓ March 19, 2026
This text was created with the support of an AI model. Editorial Responsibility: clarus.news | Fact-Check: March 19, 2026